Status:
COMPLETED
QEQ Treatment Responsiveness Evaluation Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Impotence
Eligibility:
MALE
18+ years
Phase:
PHASE4
Brief Summary
The Quality of Erection Questionnaire (QEQ) is a new questionnaire that was developed to assess erectile attributes in men with erectile dysfunction. The study objective is to validate the Quality of ...
Eligibility Criteria
Inclusion
- Subjects must have documented clinical diagnosis of erectile dysfunction based on a screening SHI-M score of \<21 and the subject fulfilling the NIH definition of erectile dysfunction
- Subjects must be either PDE-5 inhibitor naive; i.e. have never used sildenafil, tadalafil or vardenafil, or have been previously treated with no more than six doses of a PDE-5 inhibitor (sildenafil, tadalafil, vardenafil) and must have taken their last dose no less than 4 weeks prior to the screening visit
Exclusion
- Subjects who are currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00151463
Start Date
January 1 2005
Last Update
February 1 2021
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bondi Junction, New South Wales, Australia
2
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
3
Pfizer Investigational Site
St Leonards, New South Wales, Australia
4
Pfizer Investigational Site
Spring Hill, Queensland, Australia